Physician profile
Joseph D Matthews
NPI 1710984695
$2,300.63
in general payments reported to CMS, 2019-2025
14 companies · $290 in 2025
The $290 reported for 2025 was more than what 86% of Orofacial Pain providers received nationally (typical 2025 total: $95.41).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $488 · 2021: $482 · 2022: $436 · 2023: $29.77 · 2024: $13.97 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $290 · Food and Beverage: $43.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $290.49 |
| Food and Beverage | $43.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $505.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $312.45 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $293.21 | 2021 | |
| Ultradent Products INC | $290.49 | 2025 | Opalescence |
| Amgen INC. | $242.07 | 2019-2022 | |
| Abbvie INC. | $177.02 | 2022 | |
| Lilly USA, LLC | $133.68 | 2019-2022 | |
| Allergan, INC. | $123.61 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $79.28 | 2022 | |
| Merz Pharmaceuticals, LLC | $43.74 | 2023-2024 | Xeomin |
| Upsher-Smith Laboratories LLC | $37.53 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $35.69 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $13.42 | 2022 | |
| Metacel Pharmaceuticals LLC | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.